Vincenzo Adamo

8PUBLICATIONS
77CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsComputational neuroscience (incl. mathematical neuroscience and theoretical neuroscience)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 26, 2026
Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.

Giampaolo Bianchini, Luca Malorni, Roberta Caputo

|Jul 12, 2025
Efficacy and Safety Analysis of Nab-Paclitaxel Treatment in Elderly Patients with HER-2 Negative Metastatic Breast Cancer: NEREIDE Study.

Giuseppina Rosaria Rita Ricciardi, Alessandro Russo, Maria Vita Sanò

|Nov 05, 2022
Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement.

Vincenzo Adamo, Lorenzo Antonuzzo, Marco Danova

|Aug 31, 2021
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.

Marco Russano, Alessio Cortellini, Raffaele Giusti

|Nov 05, 2020
Radiomic Detection of EGFR Mutations in NSCLC.

Giovanni Rossi, Emanuele Barabino, Alessandro Fedeli

|Feb 01, 2020
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.

Alessandro Russo, Marco Russano, Tindara Franchina

Pageof 2

Frequent Collaborators

3 joint publications

Alessandro Russo

2 joint publications

Michelino De Laurentiis

1 joint publications

Emanuele Barabino

1 joint publications

Alessandro Fedeli